21 Mag Postbiotica signs a worldwide licensing agreement with Kalichem to promote postbiotic-based products in the medical device and dermocosmetic area.
Postbiotica has signed a licensing agreement with Kalichem(a Lamberti company) leader in the dermocosmetic market, based on a well established R&D collaboration. Kalichem develops and commercializes functional ingredients for cosmetics and medical devices.
The agreement relates to the licensing of Postbtiocs-based products, obtained through our PBTECH®original and patented technology.
Efficacy test on healthy volunteers have highlighted that Postbiotics are highly safe for skin and naturally stimulate the production of hyaluronic acid and collagen I, in addition they have a powerful anti-redness, soothing and immunomodulatory activity on reactive and sensitive skin. Moreover they are effective as EGF in promoting skin regeneration.
The partnership between Postbiotica and Kalichem aims to expand the use of Postbiotics in the cosmetics market worldwide. This represents a research project aimed to enlarge Kalichem portfolio and to seize new market opportunities.
Postbiotica continues to grow in different markets, including Nutraceutical and Cosmetics, thanks to the large number of Postbiotic applications; Postbiotics can be efficiently used to develop innovative, advanced, exclusive products.
Currently Postbiotica and Kalichem are working on developing innovative solutions to support the treatment of sensitive skin (like atopic dermatitis, etc.) and the antiage activity. In the near future, the collaboration between Postbiotica and Kalichem will allow exploring new frontiers of scientific research in the cosmetic chemistry, by creating a platform to develop sophisticated, targeted revolutionary products.